F8 and hemophilia: Although the baseline inhibitor risk of patients with severe hemophilia will always exceed that of patients with nonsevere hemophilia due to the absence of endogenous FVIII/FIX, EUHASS will continue to collect data on inhibitor development according to FVIII/IX concentrates.